A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy

Allergan0 sites4,385 target enrollmentApril 2009

ConditionsGlaucoma, Open-Angle Ocular Hypertension

InterventionsAny Fixed Combination Therapy

DrugsAny Fixed Combination Therapy

Overview

Phase: Not Applicable
Intervention: Any Fixed Combination Therapy
Conditions: Glaucoma, Open-Angle
Sponsor: Allergan
Enrollment: 4385
Primary Endpoint: Change From Baseline in Intraocular Pressure (IOP)
Status: Completed
Last Updated: 13 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Similar Trials

Overview

Brief Summary

This is a retrospective chart review and will assess changes in IOP after treatment with any fixed combination in patients who previously received monotherapy.

Registry

clinicaltrials.gov

Start Date

April 2009

End Date

November 2011

Last Updated

13 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Allergan

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Diagnosis of glaucoma or ocular hypertension
•Previously treated with monotherapy followed by fixed combination therapy for at least 12 weeks

Exclusion Criteria

Not provided

Arms & Interventions

POAG or OHT

Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy

Intervention: Any Fixed Combination Therapy

Outcomes

Primary Outcomes

Change From Baseline in Intraocular Pressure (IOP)

Time Frame: Baseline, 12 Weeks

IOP is a measurement of the fluid pressure inside the eye. A negative change from baseline indicates an improvement.

Secondary Outcomes

Physician Assessment of Tolerability Using a 4-Point Scale(12 Weeks)
Percentage of Patients Who Maintained Better Compliance With Treatment(12 Weeks)
Patient Assessment of Tolerability Using a 4-Point Scale(12 Weeks)
Percentage of Patients Continuing on Therapy After 12 Weeks(12 Weeks)